10 Participants Needed

Stem Cell Infusion for Kidney Transplant Tolerance

DL
JL
RW
Overseen ByRuth Wynne Jones
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: University of California, Los Angeles
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 2 JurisdictionsThis treatment is already approved in other countries

Trial Summary

Will I have to stop taking my current medications?

The trial aims to see if participants can stop taking their immunosuppressive medications after receiving a stem cell infusion. However, the protocol does not specify if you need to stop other medications, so it's best to discuss this with the trial team.

What data supports the effectiveness of the treatment Hematopoietic Stem Cell Infusion for Kidney Transplant Tolerance?

Research shows that combining kidney and hematopoietic stem cell transplants from a matched donor can help the body accept the new kidney without needing lifelong medication to suppress the immune system. Studies have reported that this approach can promote immune tolerance, reducing the risk of organ rejection and other complications.12345

Is the infusion of donor-derived hematopoietic stem cells safe for kidney transplant patients?

In clinical trials, the infusion of donor-derived hematopoietic stem cells into kidney transplant recipients has been well tolerated, with no adverse effects observed.14567

How is the treatment Hematopoietic Stem Cell Infusion unique for kidney transplant patients?

Hematopoietic Stem Cell Infusion is unique because it aims to induce immune tolerance, potentially allowing kidney transplant patients to stop using immunosuppressive drugs. This treatment involves infusing stem cells from a donor to create a state of 'chimerism' (a mix of donor and recipient cells), which helps the body accept the new kidney without rejecting it.148910

What is the purpose of this trial?

The study seeks to determine if patients with a pre-existing, well-functioning kidney transplant from a HLA-identical living donor can be withdrawn from immunosuppressive medications without compromising allograft function through hematopoietic stem cell (HPSC) infusion from the same donor. HPSC infusion will be preceded by a conditioning regimen of total lymphoid irradiation (TLI) and rabbit anti-thymocyte globulin (rATG).

Research Team

JV

Jeffrey Veale, MD

Principal Investigator

Professor of Urology

Eligibility Criteria

Adults over 18 with a well-functioning kidney transplant from an HLA-identical living donor can join. They must have good physical function, heart and liver health, no major post-transplant complications or rejection history, and stable kidney function. Women of childbearing age must use contraception.

Inclusion Criteria

My current kidney transplant has not been rejected.
Resides or is willing to stay within 3 hours distance from UCLA Medical Center by ground transportation for the first three to six months of the trial at the physician's discretion
I haven't had major issues like new cancer, infections, or rejection after my transplant.
See 11 more

Exclusion Criteria

My donor is my identical twin.
I do not have any unmanaged ongoing illnesses.
I have received transplants for more than one organ.
See 16 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Conditioning

Participants undergo a conditioning regimen with total lymphoid irradiation (TLI) and anti-thymocyte globulin (ATG) to optimize engraftment

2-4 weeks

Hematopoietic Stem Cell Infusion

Infusion of hematopoietic stem cells from the HLA-identical donor

1 day

Weaning of Immunosuppression

Weaning of tacrolimus begins at 6 months with a goal of drug discontinuation within 12 months if conditions are met

6-12 months

Follow-up

Participants are monitored for safety and effectiveness after treatment, including graft function and chimerism measurement

48 months

Treatment Details

Interventions

  • Hematopoietic Stem Cell Infusion
  • Rabbit Anti-Thymocyte Globulin
  • Total Lymphoid Irradiation
Trial Overview The trial tests if patients can stop taking anti-rejection drugs after receiving stem cells from their kidney donor. It includes a conditioning regimen with total lymphoid irradiation and rabbit anti-thymocyte globulin before the stem cell infusion.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Immune tolerance in HLA-identical kidney transplant recipientExperimental Treatment1 Intervention
We seek to establish immunological tolerance in patients with a pre-existing, well- functioning kidney transplant from an HLA-identical donor. Patients will undergo conditioning with TLI and ATG, followed by infusion of hematopoietic stem cells from the same donor . We will evaluate whether recipients can be withdrawn from immunosuppressive drugs without compromising allograft function. At serial time points, graft function will be monitored, and chimerism will be measured. Weaning of tacrolimus will begin at 6 months, with a goal of drug discontinuation within 12 months if the following conditions are met: (1) chimerism (defined as ≥1% donor type cells among the T cells, B cells, NK cells, and granulocytes) is detectable for at least 180 days, (2) stable graft function (defined as eGFR \>30 mL/min and no greater than sustained 30% change over 3 months from baseline) without clinical rejection episodes is maintained, and (3) no evidence of graft vs. host disease (GVHD).

Hematopoietic Stem Cell Infusion is already approved in United States, European Union for the following indications:

🇺🇸
Approved in United States as Hematopoietic Stem Cell Infusion for:
  • Induction of immune tolerance in kidney transplant recipients
🇪🇺
Approved in European Union as Hematopoietic Stem Cell Transplantation for:
  • Treatment of various hematologic malignancies and nonmalignant diseases
  • Induction of immune tolerance in organ transplant recipients

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of California, Los Angeles

Lead Sponsor

Trials
1,594
Recruited
10,430,000+

Findings from Research

In a study involving nine patients, the infusion of donor hematopoietic stem cells after kidney transplantation led to significant changes in protein profiles, suggesting a potential mechanism for inducing immune tolerance and preventing organ rejection.
The analysis revealed that proteins related to inflammation and the complement system were downregulated in patients receiving combined kidney and stem cell transplants, indicating a shift towards a more tolerant immune response compared to those with kidney transplants alone.
Hematopoietic stem cell transplantation induces immunologic tolerance in renal transplant patients via modulation of inflammatory and repair processes.Wu, D., Qi, G., Wang, X., et al.[2021]
Hematopoietic stem cells (HSCs) have the potential to promote immune tolerance for transplanted organs and tissues, which could help prevent rejection and improve outcomes in organ transplantation.
Recent studies have shown success in achieving durable mixed chimerism and organ allograft tolerance without causing graft-versus-host disease, indicating a promising pathway for treating various human diseases.
Manipulating the immune system for anti-tumor responses and transplant tolerance via mixed hematopoietic chimerism.Gibbons, C., Sykes, M.[2021]
Hematopoietic stem cells (HSCs) can be successfully mobilized from the peripheral blood of deceased organ donors using a combination of granulocyte colony-stimulating factor and plerixafor, which may help induce transplant tolerance without the need for lifelong immunosuppression.
Importantly, this mobilization did not lead to increased immune cell trafficking into the liver, suggesting that this method could be safely applied in deceased donor kidney transplantation without compromising liver function.
Apheresis of Deceased Donors as a New Source of Mobilized Peripheral Blood Hematopoietic Stem Cells for Transplant Tolerance.Sosa, RA., Mone, T., Naini, BV., et al.[2023]

References

Hematopoietic stem cell transplantation induces immunologic tolerance in renal transplant patients via modulation of inflammatory and repair processes. [2021]
Manipulating the immune system for anti-tumor responses and transplant tolerance via mixed hematopoietic chimerism. [2021]
Apheresis of Deceased Donors as a New Source of Mobilized Peripheral Blood Hematopoietic Stem Cells for Transplant Tolerance. [2023]
Infusion of donor-derived hematopoietic stem cells in organ transplantation: clinical data. [2004]
Tolerance induction with donor hematopoietic stem cell infusion in kidney transplantation: a single-center experience in China with a 10-year follow-up. [2022]
Incidence of chronic renal injury in patients undergoing autologous stem cell transplant therapy. [2023]
Hematopoietic stem cell infusion/transplantation for induction of allograft tolerance. [2022]
The quest for transplantation tolerance: have we finally sipped from the cup? [2021]
Successful Induction of Specific Immunological Tolerance by Combined Kidney and Hematopoietic Stem Cell Transplantation in HLA-Identical Siblings. [2022]
10.United Statespubmed.ncbi.nlm.nih.gov
Macrochimerism and clinical transplant tolerance. [2019]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security